Discovery of novel benzomorpholine derivatives as potent URAT1 inhibitors with hypouricemic effects
Bioorganic & Medicinal Chemistry Letters · 2025
DOI: 10.1016/j.bmcl.2025.130342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2025. Verfasst von Yongcheng Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences an…. Hauptthemen laut MEDLINE: Organic Cation Transport Proteins, Organic Anion Transporters, Hyperuricemia, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine.
Abstract (Originalsprache)
Urate transporter 1 (URAT1) is a clinically validated therapeutic target for hyperuricemia and gout. To obtain structurally novel URAT1 inhibitors, a series of benzomorpholine derivatives were designed by adopting a pharmacophore guided molecular hybridization strategy. Most compounds potently inhibit the human URAT1 in HEK293 cells, and the most active compound 7 exhibited an IC50 of 0.72 μM, which was much more potent than Lesinurad and comparable to Benzbromarone. The possible interaction mode of compound 7 with URAT1 was revealed by molecular modeling. Cell viability assays indicated that compound 7 was less cytotoxic than Benzbromarone in Hep-G2 cells. The urate-lowering effects of compounds 1 and 7 were confirmed in two different hyperuricemia mouse models, and no obvious toxicity was observed in the treated mice. The results provide new chemical prototypes for urate-lowering drug discovery targeting URAT1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic ad…
- Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; State Key Labor…
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
Zitieren
APA
Wang, Y., Zhang, L., Shao, M., Hou, X., Yang, Y., Yang, Y., Ye, F., Li, X., & Xiao, Z. (2025). Discovery of novel benzomorpholine derivatives as potent URAT1 inhibitors with hypouricemic effects. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2025.130342
Vancouver
Wang Y, Zhang L, Shao M, Hou X, Yang Y, Yang Y, et al. Discovery of novel benzomorpholine derivatives as potent URAT1 inhibitors with hypouricemic effects. Bioorganic & Medicinal Chemistry Letters. 2025. doi:10.1016/j.bmcl.2025.130342
BibTeX
@article{Wang2025,
author = {Wang, Yongcheng and Zhang, Lei and Shao, Mengjie and Hou, Xianxin and Yang, Ying and Yang, Yifan and Ye, Fei and Li, Xuechen and Xiao, Zhiyan},
title = {Discovery of novel benzomorpholine derivatives as potent URAT1 inhibitors with hypouricemic effects},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2025},
doi = {10.1016/j.bmcl.2025.130342}
}
EUVIMED